SCHEMBL3343897

SCHEMBL3343897

CN1CC=C(c2cn(S(=O)(=O)c3ccc4c(c3)NCCC4)c3ccc(C(F)(F)F)cc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.51
SCN9A Q15858 3/20 0.40
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336321 0.90 HTR6 (0.60) HTR6
SCHEMBL3334088 0.88 HTR6 (0.53) HTR6SCN9A
SCHEMBL3337063 0.88 HTR6 (0.66) HTR6DRD2
SCHEMBL3338498 0.85 HTR6 (0.53) HTR6SCN9A
SCHEMBL3337176 0.83 HTR6 (0.53) HTR6SCN9A
SCHEMBL4676869 0.83 HTR6 (0.64) HTR6SCN9A
Hydrochloric Acid SCHEMBL4674531 0.83 HTR6 (0.64) HTR6SCN9A
SCHEMBL3336764 0.83 HTR6 (0.55) HTR6SCN9A
Hydrochloric Acid SCHEMBL4674835 0.82 HTR6 (0.63) HTR6SCN9A
SCHEMBL4676589 0.82 HTR6 (0.74) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984351-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY Memory Pharmaceuticals Corporation (US) 2008-10-29 EP claimed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US claimed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 WO claimed
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-06-17 US disclosed
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-06-17 US disclosed
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-06-17 US disclosed
US-7696229-B2 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
US-7696229-B2 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
US-7696229-B2 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US disclosed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US disclosed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US disclosed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3B, HTR1B HTR6 1/4885SCN9A 1368/4885DRD2 18/4885
US-20080039462-A1 Compounds having 5-HT6 receptor affinity HTR6, HTR3B, HTR1B HTR6 1/4885SCN9A 1368/4885DRD2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.